SUPN Stock: Price, Earnings History and SEC Filings
Supernus Pharmaceuticals, Inc. (SUPN) last traded at $41.92, up 0.19% on the latest session and down 2.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.78 against an analyst estimate of $0.34, a beat of 129.4%.
$41.92 +0.19%
1 month-2.60%
52-week high$59.68
52-week low$37.54
Volume2.82M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SUPN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.78 | $0.34 | +129.41% |
| Jun 2026 | Aug 3, 2026 | $0.39 | $0.30 | +30.00% |
| Mar 2026 | May 5, 2026 | $0.45 | $0.14 | +221.43% |
| Dec 2025 | Feb 24, 2026 | $0.75 | $0.14 | +435.71% |
SUPN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for SUPN
SEC filing data is not available right now. You can search for SUPN on SEC EDGAR.
SUPN news
- SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior mergerNov 1, 2026 · finance.yahoo.com
- Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround NarrativeOct 30, 2026 · finance.yahoo.com
- Supernus (SUPN) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third QuarterOct 30, 2026 · finance.yahoo.com
- Supernus Pharmaceuticals Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Supernus: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (SUPN) is a US-listed public company on Nasdaq.